Wilsey Barth, Marcotte Thomas D, Deutsch Reena, Zhao Holly, Prasad Hannah, Phan Amy
VA Northern California Health Care System, Sacramento VA Medical Center, Mather, California; Department of Physical Medicine and Rehabilitation, University of California, Davis Medical Center, Lawrence J. Ellison Ambulatory Care Center, Sacramento, California.
Department of Psychiatry, University of California, San Diego, San Diego, California.
J Pain. 2016 Sep;17(9):982-1000. doi: 10.1016/j.jpain.2016.05.010. Epub 2016 Jun 7.
Using 8-hour human laboratory experiments, we evaluated the analgesic efficacy of vaporized cannabis in patients with neuropathic pain related to injury or disease of the spinal cord, most of whom were experiencing pain despite traditional treatment. After obtaining baseline data, 42 participants underwent a standardized procedure for inhaling 4 puffs of vaporized cannabis containing either placebo, 2.9%, or 6.7% delta 9-THC on 3 separate occasions. A second dosing occurred 3 hours later; participants chose to inhale 4 to 8 puffs. This flexible dosing was used to attempt to reduce the placebo effect. Using an 11-point numerical pain intensity rating scale as the primary outcome, a mixed effects linear regression model showed a significant analgesic response for vaporized cannabis. When subjective and psychoactive side effects (eg, good drug effect, feeling high, etc) were added as covariates to the model, the reduction in pain intensity remained significant above and beyond any effect of these measures (all P < .0004). Psychoactive and subjective effects were dose-dependent. Measurement of neuropsychological performance proved challenging because of various disabilities in the population studied. Because the 2 active doses did not significantly differ from each other in terms of analgesic potency, the lower dose appears to offer the best risk-benefit ratio in patients with neuropathic pain associated with injury or disease of the spinal cord.
A crossover, randomized, placebo-controlled human laboratory experiment involving administration of vaporized cannabis was performed in patients with neuropathic pain related to spinal cord injury and disease. This study supports consideration of future research that would include longer duration studies over weeks to months to evaluate the efficacy of medicinal cannabis in patients with central neuropathic pain.
通过8小时的人体实验室实验,我们评估了雾化大麻对脊髓损伤或疾病相关神经性疼痛患者的镇痛效果,这些患者中的大多数尽管接受了传统治疗仍感到疼痛。在获取基线数据后,42名参与者在3个不同场合接受了标准化程序,吸入4口分别含有安慰剂、2.9%或6.7% δ9-四氢大麻酚(delta 9-THC)的雾化大麻。3小时后进行第二次给药;参与者选择吸入4至8口。这种灵活给药方式旨在试图减少安慰剂效应。以11点数字疼痛强度评分量表作为主要结果,混合效应线性回归模型显示雾化大麻有显著的镇痛反应。当将主观和精神活性副作用(如良好的药物效果、兴奋感等)作为协变量纳入模型时,疼痛强度的降低在这些测量指标的任何效应之上仍具有显著意义(所有P < 0.0004)。精神活性和主观效应呈剂量依赖性。由于所研究人群存在各种残疾,神经心理表现的测量颇具挑战性。由于两种活性剂量在镇痛效力方面无显著差异,较低剂量似乎为脊髓损伤或疾病相关神经性疼痛患者提供了最佳的风险效益比。
对脊髓损伤和疾病相关神经性疼痛患者进行了一项涉及雾化大麻给药的交叉、随机、安慰剂对照人体实验室实验。本研究支持考虑未来开展研究,包括为期数周至数月的更长时间研究,以评估药用大麻对中枢神经性疼痛患者的疗效。